Immunolight Therapy for Cancer in Dogs
The goal of this study is to evaluate the safety of Immunolight therapy in canine cancer patients. Information gathered in this study will be used to
tell us more about how this therapy can be effectively used for treatment of various solid malignancies in dogs and people.
- Peripheral malignancies (2-6 cm) accessible for repeated intratumoral injection
- Otherwise healthy dogs, free of metastasis
- May not receive other treatments for their tumor prior to or during enrollment in study
- Predicted survival > 3 months without cancer treatment and no concurrent illness associated with a clinical prognosis for survival < 1 year
- No disease necessitating the use of chronic anti-inflammatory or immunosuppressive drug therapy, or history of autoimmune disease
- Dogs with an echocardiogram (sonogram of the heart) showing evidence of CHSA, as well as bloody effusion from a pericardial tap will be considered for the study.
- Participating dogs must be otherwise healthy and free of spread of the disease at the time of diagnosis as characterized by a physical examination, routine lab work (complete blood count, and serum chemistry panel) and diagnostic imaging (chest x-rays and an abdominal ultrasound).
- Dogs may not receive other treatments for their CHSA, including chemotherapy, homeopathic, or alternative therapies (such as Yunnan Baiyao) prior to or during enrollment in this study.
Study Benefits Include:
- Free staging tests
- Free Immunolight therapy sessions
- Free recheck examinations
- A total value of ~$4570, without the support of this clinical trial!
- Additional benefits:
- A study completion incentive of $1250
- A contribution of up to $1000 for treatment of unexpected complications directly associated
with Immunolight therapy. Care for side effects must be provided at NC State, under the
guidance of a radiation oncologist.
Page last updated September 18, 2014